Article
Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.
Lung cancer (Amsterdam, Netherlands) - 1 Sept 2017
Oztan A, Fischer S, Schrock A B, Erlich R L, Lovly C M, Stephens P J, Ross J S, Miller V, Ali S M, Ou S-H I, Raez L E
Abstract excerpt
Mutations in the epidermal growth factor receptor (EGFR) are drivers for a subset of lung cancers. Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) recently approved for the treatment of T790M-positive non-small cell lung cancer (NSCLC); however, acquired resistance to osimertinib is evident and resistance mechanisms remain incompletely defined. The EGFR G724S mutation was detected using...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.